EP1624068A1
(de)
|
1993-06-01 |
2006-02-08 |
Life Technologies Inc. |
Genetische Impfung mit kationischen Lipidstoffen
|
US5674908A
(en)
|
1993-12-20 |
1997-10-07 |
Life Technologies, Inc. |
Highly packed polycationic ammonium, sulfonium and phosphonium lipids
|
US6989434B1
(en)
*
|
1994-02-11 |
2006-01-24 |
Invitrogen Corporation |
Reagents for intracellular delivery of macromolecules
|
US5651981A
(en)
*
|
1994-03-29 |
1997-07-29 |
Northwestern University |
Cationic phospholipids for transfection
|
WO1995035301A1
(en)
*
|
1994-06-22 |
1995-12-28 |
Megabios Corporation |
Cationic amphiphiles
|
CA2223179A1
(en)
*
|
1995-06-07 |
1996-12-19 |
Bob Dale Brown |
Phosphonic acid-based cationic lipids
|
US5932241A
(en)
*
|
1995-06-07 |
1999-08-03 |
Valentis, Incorporated |
Cationic lipid DNA complexes for gene targeting
|
US5855911A
(en)
*
|
1995-08-29 |
1999-01-05 |
Board Of Regents, The University Of Texas System |
Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
|
EP0871758B1
(de)
*
|
1995-11-21 |
2004-03-31 |
KINNUNEN, Paavo Kai Johannes |
Transfektionsverfahren mit hilfe von liposomen
|
US7309692B1
(en)
*
|
1996-07-08 |
2007-12-18 |
Board Of Regents, The University Of Texas System |
Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1
|
US6977244B2
(en)
*
|
1996-10-04 |
2005-12-20 |
Board Of Regents, The University Of Texas Systems |
Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
|
US7704962B1
(en)
|
1997-10-03 |
2010-04-27 |
Board Of Regents, The University Of Texas System |
Small oligonucleotides with anti-tumor activity
|
US7285288B1
(en)
|
1997-10-03 |
2007-10-23 |
Board Of Regents, The University Of Texas System |
Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
|
US5998482A
(en)
*
|
1997-11-10 |
1999-12-07 |
David; Sunil A. |
Use of synthetic polycationic amphiphilic substances with fatty acid or hydrocarbon substituents as anti-sepsis agents
|
AU5366099A
(en)
|
1998-08-20 |
2000-03-14 |
Connaught Laboratories Limited |
Nucleic acid molecules encoding inclusion membrane protein of (chlamydia)
|
US6693087B1
(en)
|
1998-08-20 |
2004-02-17 |
Aventis Pasteur Limited |
Nucleic acid molecules encoding POMP91A protein of Chlamydia
|
US6686339B1
(en)
|
1998-08-20 |
2004-02-03 |
Aventis Pasteur Limited |
Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
|
US6913749B2
(en)
*
|
1998-11-02 |
2005-07-05 |
Resistentia Pharmaceuticals Ab |
Immunogenic polypeptides for inducing anti-self IgE responses
|
EP1129064B1
(de)
|
1998-11-12 |
2008-01-09 |
Invitrogen Corporation |
Transportreagentien
|
US6281005B1
(en)
|
1999-05-14 |
2001-08-28 |
Copernicus Therapeutics, Inc. |
Automated nucleic acid compaction device
|
US6677445B1
(en)
|
1999-08-27 |
2004-01-13 |
Chiron Corporation |
Chimeric antisense oligonucleotides and cell transfecting formulations thereof
|
EP1808180A3
(de)
|
1999-10-22 |
2010-12-22 |
Sanofi Pasteur Limited |
Modifiziertes GP 100 und Verwendung dafür
|
US20040146918A1
(en)
*
|
2000-02-18 |
2004-07-29 |
Weiner Michael L. |
Hybrid nucleic acid assembly
|
EP1792995A3
(de)
|
2000-05-08 |
2007-06-13 |
Sanofi Pasteur Limited |
Chlamydia Antigene, entsprechende DNS Fragmente und ihre Verwendungen
|
AU2001258102B2
(en)
*
|
2000-05-10 |
2007-03-01 |
Aventis Pasteur Limited |
Immunogenic polypeptides encoded by mage minigenes and uses thereof
|
WO2002062989A2
(en)
*
|
2001-02-08 |
2002-08-15 |
Sequitur, Inc. |
Methods of light activated release 0f ligands from endosomes
|
CA2471967A1
(en)
*
|
2002-01-03 |
2003-07-31 |
Board Of Regents, The University Of Texas System |
Wt1 antisense oligos for the inhibition of breast cancer
|
CA2475003A1
(en)
|
2002-02-01 |
2003-08-07 |
Sequitur, Inc. |
Double-stranded oligonucleotides
|
US20060009409A1
(en)
|
2002-02-01 |
2006-01-12 |
Woolf Tod M |
Double-stranded oligonucleotides
|
US20030166282A1
(en)
*
|
2002-02-01 |
2003-09-04 |
David Brown |
High potency siRNAS for reducing the expression of target genes
|
DE60315628T2
(de)
|
2002-04-09 |
2008-06-05 |
Sanofi Pasteur Ltd., Toronto |
Modifizierte cea nucleinsäure und expressionsvektoren
|
EP1356820A1
(de)
|
2002-04-26 |
2003-10-29 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
DNA-Impfstoff kombiniert mit einen Apoptoneauslöser von Tumorzellen
|
US20040248094A1
(en)
*
|
2002-06-12 |
2004-12-09 |
Ford Lance P. |
Methods and compositions relating to labeled RNA molecules that reduce gene expression
|
US20040029275A1
(en)
*
|
2002-08-10 |
2004-02-12 |
David Brown |
Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
|
DE10245909A1
(de)
*
|
2002-10-01 |
2004-04-15 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Lipidanaloge Phosphorsäuretriester
|
EP1587908A4
(de)
*
|
2003-01-09 |
2008-02-20 |
Invitrogen Corp |
Zelluläre zuführung und aktivierung von polypeptid-nukleinsäurekomplexen
|
US8562970B2
(en)
*
|
2003-10-08 |
2013-10-22 |
Sanofi Pasteur Limited |
Modified CEA/B7 vector
|
WO2005059163A2
(en)
*
|
2003-12-15 |
2005-06-30 |
Applera Corporation |
Methods, compositions, and kits for analysis of enzyme activity in cells
|
US9315862B2
(en)
*
|
2004-10-05 |
2016-04-19 |
California Institute Of Technology |
Aptamer regulated nucleic acids and uses thereof
|
US20060211004A1
(en)
|
2005-02-15 |
2006-09-21 |
Ilsley Diane D |
Methods and compositions for determining non-specific cytotoxicity of a transfection agent
|
WO2008001166A2
(en)
*
|
2006-02-07 |
2008-01-03 |
Council Of Scientific & Industrial Research |
Process for synthesis of glycomimicking cationic amphiphiles
|
GB0606190D0
(en)
|
2006-03-28 |
2006-05-10 |
Isis Innovation |
Construct
|
DE102006028983A1
(de)
*
|
2006-06-23 |
2007-12-27 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Phosphorsäurediesteramide
|
US8158595B2
(en)
|
2006-11-09 |
2012-04-17 |
California Institute Of Technology |
Modular aptamer-regulated ribozymes
|
WO2009011855A2
(en)
*
|
2007-07-16 |
2009-01-22 |
California Institute Of Technology |
Selection of nucleic acid-based sensor domains within nucleic acid switch platform
|
US20120165387A1
(en)
|
2007-08-28 |
2012-06-28 |
Smolke Christina D |
General composition framework for ligand-controlled RNA regulatory systems
|
US8367815B2
(en)
*
|
2007-08-28 |
2013-02-05 |
California Institute Of Technology |
Modular polynucleotides for ligand-controlled regulatory systems
|
US8865667B2
(en)
|
2007-09-12 |
2014-10-21 |
California Institute Of Technology |
Higher-order cellular information processing devices
|
EP2219587A4
(de)
*
|
2007-11-14 |
2012-11-21 |
Univ California |
Sterol-modifizierte amphiphile lipide
|
US9029524B2
(en)
*
|
2007-12-10 |
2015-05-12 |
California Institute Of Technology |
Signal activated RNA interference
|
CA2715289C
(en)
|
2008-02-11 |
2019-12-24 |
Rxi Pharmaceuticals Corporation |
Modified rnai polynucleotides and uses thereof
|
US8815818B2
(en)
|
2008-07-18 |
2014-08-26 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell delivery of RNAI
|
PT104158B
(pt)
*
|
2008-08-18 |
2011-02-24 |
Univ Do Minho |
Aplicação da monooleína como novo lípido adjuvante em lipofecção
|
CN108165548B
(zh)
|
2008-09-22 |
2022-10-14 |
菲奥医药公司 |
减小大小的自递送RNAi化合物
|
US9074211B2
(en)
|
2008-11-19 |
2015-07-07 |
Rxi Pharmaceuticals Corporation |
Inhibition of MAP4K4 through RNAI
|
WO2010078536A1
(en)
|
2009-01-05 |
2010-07-08 |
Rxi Pharmaceuticals Corporation |
Inhibition of pcsk9 through rnai
|
WO2010090762A1
(en)
|
2009-02-04 |
2010-08-12 |
Rxi Pharmaceuticals Corporation |
Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
US8329882B2
(en)
|
2009-02-18 |
2012-12-11 |
California Institute Of Technology |
Genetic control of mammalian cells with synthetic RNA regulatory systems
|
EP2411519B1
(de)
|
2009-03-27 |
2015-07-22 |
Institut National de la Santé et de la Recherche Médicale |
Kanamycin-antisense-nucleinsäure zur behandlung von krebs
|
US9145555B2
(en)
|
2009-04-02 |
2015-09-29 |
California Institute Of Technology |
Integrated—ligand-responsive microRNAs
|
AU2010245933B2
(en)
*
|
2009-05-05 |
2016-06-16 |
Arbutus Biopharma Corporation |
Methods of delivering oligonucleotides to immune cells
|
US20120237589A1
(en)
|
2009-07-09 |
2012-09-20 |
Marina Biotech, Inc. |
Amphoteric liposomes comprising imino lipids
|
GB0918679D0
(en)
|
2009-10-23 |
2009-12-09 |
Iqur Ltd |
Influenza vaccine
|
GB0918782D0
(en)
|
2009-10-26 |
2009-12-09 |
St Georges Hosp Medical School |
A protein as an adjuvant for a vaccine
|
GB201004475D0
(en)
|
2010-03-17 |
2010-05-05 |
Isis Innovation |
Gene silencing
|
EP2550001B1
(de)
|
2010-03-24 |
2019-05-22 |
Phio Pharmaceuticals Corp. |
Rna-interferenz bei augenerkrankungen
|
KR20180044433A
(ko)
|
2010-03-24 |
2018-05-02 |
알엑스아이 파마슈티칼스 코포레이션 |
진피 및 섬유증성 적응증에서의 rna 간섭
|
EP2576613A1
(de)
|
2010-06-07 |
2013-04-10 |
Pfizer Inc. |
Her-2-peptide und impfstoffe
|
GB201014026D0
(en)
|
2010-08-20 |
2010-10-06 |
Ucl Business Plc |
Treatment
|
WO2012035557A1
(en)
|
2010-09-14 |
2012-03-22 |
Council Of Scientific & Industrial Research |
Novel cationic amphiphiles with mannose-mimicking head-groups and a process for the preparation thereof
|
JP6261500B2
(ja)
|
2011-07-22 |
2018-01-17 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
ヌクレアーゼ切断特異性の評価および改善
|
WO2013119602A1
(en)
|
2012-02-06 |
2013-08-15 |
President And Fellows Of Harvard College |
Arrdc1-mediated microvesicles (armms) and uses thereof
|
US9879012B2
(en)
|
2012-03-29 |
2018-01-30 |
Regents Of The University Of Colorado, A Body Corporate |
Click nucleic acids
|
PE20142406A1
(es)
|
2012-05-04 |
2015-01-23 |
Pfizer |
Antigenos asociados a prostata y regimenes de inmunoterapia basados en vacuna
|
JP6392315B2
(ja)
|
2013-03-14 |
2018-09-19 |
イミュソフト コーポレーション |
インビトロでのメモリーb細胞分化方法およびvsv−g偽型ウイルスベクターを用いる形質導入方法
|
US20160122420A1
(en)
|
2013-06-06 |
2016-05-05 |
Rowlands David J |
Antibody display
|
US20150044192A1
(en)
|
2013-08-09 |
2015-02-12 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a cas9 nuclease
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
US9340800B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
Extended DNA-sensing GRNAS
|
WO2016070129A1
(en)
|
2014-10-30 |
2016-05-06 |
President And Fellows Of Harvard College |
Delivery of negatively charged proteins using cationic lipids
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
US9322037B2
(en)
|
2013-09-06 |
2016-04-26 |
President And Fellows Of Harvard College |
Cas9-FokI fusion proteins and uses thereof
|
AU2014346559B2
(en)
|
2013-11-07 |
2020-07-09 |
Editas Medicine,Inc. |
CRISPR-related methods and compositions with governing gRNAs
|
JP6883987B2
(ja)
|
2013-12-04 |
2021-06-09 |
フィオ ファーマシューティカルズ コーポレーションPhio Pharmaceuticals Corp. |
化学修飾されたオリゴヌクレオチドを利用する創傷治癒の処置のための方法
|
US9840699B2
(en)
|
2013-12-12 |
2017-12-12 |
President And Fellows Of Harvard College |
Methods for nucleic acid editing
|
EP3137119B1
(de)
|
2014-04-28 |
2020-07-01 |
Phio Pharmaceuticals Corp. |
Verfahren zur behandlung von krebs mithilfe von einer nukleinsaüre gegen mdm2
|
WO2015168605A1
(en)
|
2014-05-01 |
2015-11-05 |
Rxi Pharmaceuticals Corporation |
Methods for treatment of disorders in the front of the eye utilizing nucleic acid molecules
|
EP3169310A1
(de)
|
2014-07-15 |
2017-05-24 |
Life Technologies Corporation |
Zusammensetzungen mit lipidaggregaten und verfahren zur effizienten bereitstellung von molekülen an zellen
|
CA2956224A1
(en)
|
2014-07-30 |
2016-02-11 |
President And Fellows Of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
EP3188799B1
(de)
|
2014-09-05 |
2022-07-06 |
Phio Pharmaceuticals Corp. |
Verfahren zur behandlung von alterung und hauterkrankungen mit auf tyr oder mmp1 gerichteten nukleinsäuren
|
US9816080B2
(en)
|
2014-10-31 |
2017-11-14 |
President And Fellows Of Harvard College |
Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
|
EP3234107B1
(de)
|
2014-12-19 |
2022-09-14 |
Immusoft Corporation |
B-zellen zur in-vivo-verabreichung von therapeutika
|
WO2017007825A1
(en)
|
2015-07-06 |
2017-01-12 |
Rxi Pharmaceuticals Corporation |
Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
|
WO2017007813A1
(en)
|
2015-07-06 |
2017-01-12 |
Rxi Pharmaceuticals Corporation |
Nucleic acid molecules targeting superoxide dismutase 1 (sod1)
|
WO2017070151A1
(en)
|
2015-10-19 |
2017-04-27 |
Rxi Pharmaceuticals Corporation |
Reduced size self-delivering nucleic acid compounds targeting long non-coding rna
|
IL310721A
(en)
|
2015-10-23 |
2024-04-01 |
President And Fellows Of Harvard College |
Nucleobase editors and their uses
|
BR112018013967A2
(pt)
|
2016-01-19 |
2019-02-05 |
Pfizer |
vacinas contra o câncer
|
KR20230095129A
(ko)
|
2016-08-03 |
2023-06-28 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
아데노신 핵염기 편집제 및 그의 용도
|
CN109804066A
(zh)
|
2016-08-09 |
2019-05-24 |
哈佛大学的校长及成员们 |
可编程cas9-重组酶融合蛋白及其用途
|
US11542509B2
(en)
|
2016-08-24 |
2023-01-03 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
KR20240007715A
(ko)
|
2016-10-14 |
2024-01-16 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
핵염기 에디터의 aav 전달
|
CN109996809A
(zh)
|
2016-11-14 |
2019-07-09 |
诺华股份有限公司 |
与促融合蛋白minion相关的组合物、方法和治疗用途
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
US11898179B2
(en)
|
2017-03-09 |
2024-02-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
WO2018165629A1
(en)
|
2017-03-10 |
2018-09-13 |
President And Fellows Of Harvard College |
Cytosine to guanine base editor
|
IL269458B2
(en)
|
2017-03-23 |
2024-02-01 |
Harvard College |
Nucleic base editors that include nucleic acid programmable DNA binding proteins
|
US11560566B2
(en)
|
2017-05-12 |
2023-01-24 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
|
US11732274B2
(en)
|
2017-07-28 |
2023-08-22 |
President And Fellows Of Harvard College |
Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
|
EP3676376A2
(de)
|
2017-08-30 |
2020-07-08 |
President and Fellows of Harvard College |
Hocheffiziente baseneditoren mit gam
|
WO2019057649A1
(en)
|
2017-09-19 |
2019-03-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA
|
US11795443B2
(en)
|
2017-10-16 |
2023-10-24 |
The Broad Institute, Inc. |
Uses of adenosine base editors
|
RU2020133851A
(ru)
|
2018-03-16 |
2022-04-19 |
Иммьюсофт Корпорейшн |
B-клетки, генетически модифицированные для секреции фоллистатина, и способы их применения для лечения связанных с фоллистатином заболеваний, состояний, нарушений и для увеличения роста и силы мышц
|
GB201811382D0
(en)
|
2018-07-11 |
2018-08-29 |
Taylor John Hermon |
Vaccine
|
US20230048010A1
(en)
|
2018-09-28 |
2023-02-16 |
President And Fellows Of Harvard College |
Cellular reprogramming to reverse aging and promote organ and tissue regeneration
|
WO2020191248A1
(en)
|
2019-03-19 |
2020-09-24 |
The Broad Institute, Inc. |
Method and compositions for editing nucleotide sequences
|
IT201900007060A1
(it)
|
2019-05-21 |
2020-11-21 |
St Superiore Di Sanita |
Cellule tumorali ingegnerizzate e loro usi
|
WO2021005223A1
(en)
|
2019-07-10 |
2021-01-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of epilepsy
|
IT201900012540A1
(it)
|
2019-07-22 |
2021-01-22 |
Humanitas Mirasole Spa |
Inibitori di CHI3L1 e loro usi
|
EP4055167A2
(de)
|
2019-11-08 |
2022-09-14 |
Phio Pharmaceuticals Corp. |
Auf das bromodomainhaltige protein 4 (brd4) abzielende chemisch modifizierte oligonukleotide für die immuntherapie
|
WO2021099394A1
(en)
|
2019-11-19 |
2021-05-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antisense oligonucleotides and their use for the treatment of cancer
|
WO2021138537A1
(en)
|
2019-12-31 |
2021-07-08 |
Phio Pharmaceuticals Corp. |
Chemically modified oligonucleotides with improved systemic delivery
|
JP2023525304A
(ja)
|
2020-05-08 |
2023-06-15 |
ザ ブロード インスティテュート,インコーポレーテッド |
標的二本鎖ヌクレオチド配列の両鎖同時編集のための方法および組成物
|
WO2021255262A1
(en)
|
2020-06-19 |
2021-12-23 |
Sylentis Sau |
siRNA AND COMPOSITIONS FOR PROPHYLACTIC AND THERAPEUTIC TREATMENT OF VIRUS DISEASES
|
EP4015634A1
(de)
|
2020-12-15 |
2022-06-22 |
Sylentis, S.A.U. |
Sirna und zusammensetzungen zur prophylaktischen und therapeutischen behandlung von viruskrankheiten
|
WO2023012165A1
(en)
|
2021-08-02 |
2023-02-09 |
Universite De Montpellier |
Compositions and methods for treating cmt1a or cmt1e diseases with rnai molecules targeting pmp22
|
WO2023015265A2
(en)
|
2021-08-04 |
2023-02-09 |
Phio Pharmaceuticals Corp. |
Chemically modified oligonucleotides
|
WO2023015264A1
(en)
|
2021-08-04 |
2023-02-09 |
Phio Pharmaceuticals Corp. |
Immunotherapy of cancer utilizing natural killer cells treated with chemically modified oligonucleotides
|
WO2023196851A1
(en)
|
2022-04-06 |
2023-10-12 |
President And Fellows Of Harvard College |
Reversing aging of the central nervous system
|
WO2024017990A1
(en)
|
2022-07-21 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating chronic pain disorders
|